|
Novel Therapeutic Strategy for Refractory and Relapse Childhood Acute Leukemia
|
1R43CA171344-01A1
|
$240,322
|
$240,322
|
Haslanger, Martin
|
APEX THERAPEUTICS, INC.
|
|
Germline Telomere Biology Defects in Pediatric and Young Adult Acute Myeloid Leuk
|
5K23CA158148-02
|
$168,578
|
$168,578
|
Gramatges, Maria
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
1R01CA164024-01A1
|
$385,859
|
$385,859
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
|
1R01CA163849-01A1
|
$477,421
|
$238,711
|
Justice, Monica
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S1
|
$75,000
|
$2,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S2
|
$43,265
|
$1,298
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-07
|
$3,092,811
|
$92,784
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-11
|
$24,894,951
|
$14,688,021
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Genetic Predictors of AML Treatment Response
|
5R01CA133881-04
|
$522,609
|
$522,609
|
Aplenc, Richard
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Toxicity Monitoring on Phase III Trials with Administrative Data
|
5R01CA165277-02
|
$461,557
|
$461,557
|
Aplenc, Richard
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
MLL in Hematopoiesis and Leukemia in the Zebrafish Model
|
5R01CA153348-04
|
$375,268
|
$375,268
|
Felix, Carolyn
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Bone Deficits and Excess Adiposity after Pediatric Bone Marrow Transplantation
|
1K07CA166177-01A1
|
$165,004
|
$165,004
|
Mostoufi-Moab, Sogol
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-09
|
$306,016
|
$76,504
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
5U54CA163117-03
|
$456,366
|
$123,219
|
DeClerck, Yves
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
|
1R01CA172896-01A1
|
$347,041
|
$347,041
|
Kim, Yong-Mi
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Investigating the Role of Adipocytes on Leukemia Relapse
|
5R01CA139060-05
|
$303,097
|
$303,097
|
Mittelman, Steven
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL
|
5R01CA154471-03
|
$312,080
|
$312,080
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Amplifying Radiation Potency Against Leukemic Stem Cells
|
5R21CA164098-02
|
$165,605
|
$165,605
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles
|
5U01CA151837-04
|
$416,542
|
$416,542
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-03
|
$298,427
|
$298,427
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting non-classical oncogenes as therapy for T-ALL
|
5R01CA169162-02
|
$312,080
|
$156,040
|
Diacovo, Thomas
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S3
|
$3,546,194
|
$106,386
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S4
|
$75,000
|
$2,250
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S5
|
$125,000
|
$3,750
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-39S6
|
$49,718
|
$1,492
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of ETV6 in T-cell acute lymphoblastic leukemia
|
1R01CA172398-01
|
$332,000
|
$166,000
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of PHF6 in T-cell acute lymphoblastic leukemia
|
5R01CA155743-03
|
$312,080
|
$312,080
|
Ferrando, Adolfo
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of FBXL4 in T-cell Acute Lymphoblastic Leukemia
|
1F30CA174099-01
|
$41,377
|
$20,689
|
Haydu, Julie-Erika
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA006516-48S1
|
$114,538
|
$5,727
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-48S3
|
$12,500
|
$625
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-48S4
|
$50,000
|
$2,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-48
|
$10,435,722
|
$521,786
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Molecular Pathways to Thynmic Lymphoma and Leukemia
|
5P01CA109901-09
|
$1,895,397
|
$1,364,686
|
LOOK, A
|
DANA-FARBER CANCER INST
|
|
Discovery of New Targets and Pathways for T-ALL Therapy
|
5R01CA176746-02
|
$356,250
|
$356,250
|
LOOK, A
|
DANA-FARBER CANCER INST
|
|
Research Training in Pediatric Oncology
|
5T32CA136432-05
|
$503,533
|
$503,533
|
ORKIN, STUART
|
DANA-FARBER CANCER INST
|
|
Validating Syk as a Target for AML Therapy
|
5R01CA140292-05
|
$331,098
|
$331,098
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
Polysomy 21 in Acute Lymphoblastic Leukemia
|
1R01CA172387-01A1
|
$352,946
|
$176,473
|
Weinstock, David
|
DANA-FARBER CANCER INST
|
|
Phenotype-Genotype Associations with Symptoms During Childhood Leukemia Treatment
|
5R01CA169398-02
|
$550,174
|
$550,174
|
HOCKENBERRY, MARILYN
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-39S1
|
$18,744
|
$375
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
5P30CA014236-39
|
$5,351,774
|
$107,035
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Feasibility of a Couple-based Intervention for Parents of Children with Cancer
|
5R21CA164817-02
|
$192,592
|
$48,148
|
PORTER, LAURA
|
DUKE UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-05S2
|
$37,430
|
$374
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-05
|
$1,396,397
|
$13,964
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
2R01CA123490-06A1
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Berberine downregulates MDM2 by interaction with DAXX in cancer cells
|
5R01CA143107-04
|
$293,258
|
$146,629
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
EORTC HEADQUARTERS
|
4U10CA011488-43
|
$250,025
|
$37,504
|
Lacombe, Denis
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Protein Biomarkers in Childhood Acute Myeloid Leukemia
|
5R21CA164545-02
|
$194,919
|
$194,919
|
BEDALOV, ANTONIO
|
FRED HUTCHINSON CAN RES CTR
|
|
Pediatric Oncology Research Training Program
|
5T32CA009351-35
|
$239,826
|
$35,974
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CAN RES CTR
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S1
|
$109,383
|
$2,188
|
Corey, Lawrence
|
FRED HUTCHINSON CAN RES CTR
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S2
|
$18,750
|
$375
|
Corey, Lawrence
|
FRED HUTCHINSON CAN RES CTR
|
Total relevant funding to Childhood Leukemia for this search: $57,019,078
|